Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy

Table 1 Basic clinical data, details of arthropathy, serologic findings, and therapy

Case	Age/gender	Clinical presentation and arthropathy	Spleen, mm	ANA	RF IgM, IU/mL	ANCA	CCP	aCL	HP	Therapy
1	84/F	RA (43 y), BCC (7 m), AITD, weight loss	120	1/160	423	Neg	Pos	Pos	Yes	Corticosteroids
2	56/F	RA (10 y), BCC (6 y), amyloidosis AA	115	1/160	320	Neg	Pos	ND	Yes	Corticosteroids
3	75/F	RA (7 y), BCC (2 y), weight loss	180	1/160	125	Neg	Pos	ND	Yes	Corticosteroids
4	36/F	RA (18 y), BCC (4 y), AITD	187	1/160	335	Neg	Pos	ND	Yes	Corticosteroids/MTX
5	58/F	RA (32 y), BCC (1 y), AITD	95	1/160	97	Neg	Pos	ND	Yes	Corticosteroids/MTX
6	74/M	RA (10 y), BCC (3 y)	150	1/320	325	Neg	Pos	Pos	Yes	Unknown
7	57/M	RA (10 y), BCC (3 y)	200	1/160	320	ND	Pos	ND	Yes	Corticosteroids/MTX
8	52/F	UA (12 y), BCC (3 y), recurrent infections, skin lesions	160	1/320	Neg	Neg	ND	Pos	Yes	Corticosteroids
9	68/F	BCC (17 y), UA (2 y), recurrent infections, skin lesions	185	1/80 dsDNA	97	Neg	Pos	Pos	Yes	G-CSF/MTX
10	51/F	RA (8 y), rheumatoid nodules, BCC (3 y)	185	1/160	450	Neg	Pos	Pos	Yes	MTX/CSA/Corticosteroids
11	35/F	RA (5 y), BCC (6 m)	86	1/320	640	ND	Pos	ND	Yes	Corticosteroids
12	50/F	BCC (6 m)	113	1/80	29	Pos/Neg	Neg	Pos	Yes	MTX
13	28/F	BCC (10 y), AITD	103	Neg	ND	ND	ND	ND	Yes	None
14	47/F	BCC (1 y), AITD	130	ND	ND	ND	ND	ND	No	Corticosteroids/MTX
15	55/F	BCC (1 y), glomerulonephritis (10 y)	200	ND	ND	ND	ND	ND	Yes	MTX/Corticosteroids
16	52/F	BCC (2 y)	115	Neg	Neg	Neg	ND	ND	Yes	CSA/G-CSF
17	54/M	BCC (3 y)	145	Neg	Neg	Neg	ND	ND	No	Unknown
18	70/M	BCC (1 y), weight loss, skin lesions	115	ND	ND	ND	ND	ND	No	MTX/Corticosteroids
19	66/F	BCC, recurrent infections, weight loss (10 y)	120	Neg	Neg	ND	ND	ND	Yes	Unknown
20	69/F	BCC (6 y)	125	Neg	Neg	ND	ND	ND	Yes	Unknown
21	33/F	BCC (6 m)	150	1/80	160	ND	ND	ND	Yes	CSA

aCL, anticardiolipin antibody; AITD, autoimmune thyroiditis; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; BCC, blood cell count abnormalities; CCP, anticyclic citrullinated peptide antibodies; CSA, cyclosporine A; dsDNA, double-stranded DNA; F, female; G-CSF, granulocyte-colony stimulating factor; HP, polyclonal hipergammaglobulinemia; m, months of observation; M, male; MTX, methotrexate; ND, not done; Neg, negative; Pos, positive; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, unclassified arthritis; y, years of observation.

ISSN: 1478-6362